Welcome to our dedicated page for ACADIA PHARMACEUTICALS SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acadia Pharmaceuticals Inc. filings document the regulatory record for a commercial biopharmaceutical company focused on neurological and rare diseases. Recent Form 8-K reports furnish quarterly and annual operating results, product-sales disclosures for NUPLAZID and DAYBUE, corporate presentations and Regulation FD materials, and updates tied to research-and-development leadership.
Proxy and governance filings describe board composition, committee service, director compensation, executive compensation, equity-incentive awards and annual meeting matters. The filings also record board appointments and resignations, non-employee director compensation under equity plans, and other material-event disclosures affecting Acadia’s governance and capital structure.
ACADIA PHARMACEUTICALS INC director Adora Ndu reported equity compensation activity and an option exercise. On May 29, 2026, Ndu exercised restricted stock units covering 8,107 shares of common stock, bringing direct common stock holdings to 32,908 shares.
Ndu also received 9,311 new restricted stock units and 16,004 director stock options with an exercise price of $21.66 per share. According to the footnotes, the 9,311 restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting, while the options vest quarterly over one year on a similar schedule. The filing shows compensation-related awards and conversions, with no open-market purchases or sales.
ACADIA PHARMACEUTICALS INC director Laura Brege reported equity compensation and option activity. She exercised 8,107 previously granted restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 23,202 shares.
On the same date, she received a new grant of 9,311 restricted stock units, each representing a right to one share of common stock, and a grant of 16,004 director stock options with an exercise price of $21.66 per share, expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting. Brege has elected to defer receipt of the shares underlying the new restricted stock units until specified future events such as a set anniversary date, ceasing board service, or a change in control under the company’s 2024 Equity Incentive Plan.
ACADIA PHARMACEUTICALS INC director Jonathan Poole reported equity compensation activity, including option exercises and new awards. He exercised derivative securities for 2,010 shares of common stock and now holds 2,010 common shares directly. He also received 9,311 restricted stock units and 16,004 director stock options.
The 9,311 restricted stock units each represent a right to one share of common stock and will vest in full on the earlier of one year from grant or the next annual stockholder meeting, with settlement deferred based on his election. The 16,004 stock options vest quarterly over one year following the grant date and have an exercise price of $21.66 per share.
ACADIA PHARMACEUTICALS director Elizabeth A. Garofalo reported equity compensation activity centered on RSUs and stock options. On May 29, 2026, she exercised 8,107 restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 33,489 shares.
She also received a new grant of 9,311 restricted stock units, each representing one future share of common stock, and 16,004 director stock options with a strike price of $21.66 per share that vest quarterly over one year. The new RSUs will vest in full on the earlier of one year from grant or the next annual meeting, and she has elected to defer receipt of the underlying shares until specified future triggers.
ACADIA PHARMACEUTICALS director James M. Daly reported equity compensation activity on May 29, 2026. He exercised previously granted restricted stock units, receiving 8,107 shares of common stock, and held 12,148 common shares directly after these transactions.
On the same date, he was granted 9,311 restricted stock units, each representing one share of common stock, and 16,004 director stock options with an exercise price of $21.66 per share expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units are scheduled to vest in full on the earlier of one year after grant or the next annual meeting, with Daly electing to defer receipt of the underlying shares under the company’s 2024 Equity Incentive Plan.
Acadia Pharmaceuticals Inc. reported that stockholders approved an amendment to its 2024 Equity Incentive Plan, increasing the number of common shares authorized for issuance under the plan by 5,209,670. This approval occurred at the company’s 2026 Annual Meeting of Stockholders, following prior approval of the amendment by the board.
At the meeting, three Class I directors were elected, with each nominee receiving over 128 million votes in favor. Stockholders also approved the other proposals presented, with support levels generally above 147 million votes for key items, and the company has filed the amended equity plan as Exhibit 10.1.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara sold 5,401 shares of common stock in an open-market sale at a weighted average price of $21.18 per share. After the transaction, he directly owns 24,509 shares, including 781 shares acquired on May 15, 2026 through an employee stock purchase plan.
ACAD Form 144 filing lists proposed sales of Common stock tied to several benefit plans and recent dispositions by a reported holder. The excerpt shows Performance Shares: 3,857 and Employee Stock Purchase Plan allocations of 491 and 1,053. It also records four reported past dispositions by James Kihara totaling 4,304 shares on 03/25/2026, 03/26/2026, 04/07/2026, and 05/04/2026
ACADIA Pharmaceuticals reported modest revenue growth but sharply lower profit for the quarter ended March 31, 2026. Net product sales reached $268.1 million, up from $244.3 million a year earlier, driven by NUPLAZID at $166.9 million and DAYBUE at $101.2 million.
Despite higher sales, net income fell to $3.6 million from $19.0 million as selling, general and administrative expenses rose to $171.0 million, reflecting heavier commercial investment, while research and development spending remained roughly flat at $76.9 million. Cash, cash equivalents and investment securities totaled $851.5 million, and operating cash flow improved to $34.0 million, indicating the company is funding growth while maintaining a strong liquidity position.
Acadia Pharmaceuticals reported first quarter 2026 total revenues of $268 million, up 10% from $244 million a year earlier, driven by neurology drugs NUPLAZID and DAYBUE. GAAP net product sales were $167 million for NUPLAZID, up 5% year-over-year, and $101 million for DAYBUE, up 20% year-over-year, helped by the U.S. launch of the DAYBUE STIX formulation.
Research and development expenses were $77 million, roughly flat versus 2025, while selling, general and administrative expenses rose to $171 million from $126 million as the company invested behind commercial growth. Net income declined to $3.6 million, or $0.02 per diluted share, from $19.0 million, reflecting higher operating costs. Cash, cash equivalents and investment securities totaled $851 million as of March 31, 2026. Acadia reaffirmed its full-year 2026 guidance, including total revenues of $1.22–$1.28 billion, NUPLAZID net product sales of $760–$790 million, DAYBUE net product sales of $460–$490 million, and R&D and SG&A expense ranges. The company also highlighted upcoming Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis expected between August and October 2026.